Sanguine Release: Lifescience Industry Veteran Susan Aroyan Joins Sanguine As Chief Strategy Officer

LOS ANGELES, Aug. 18, 2015 /PRNewswire/ -- Sanguine (https://www.sanguinebio.com/), a leading technology company providing services to the personalized medicine and biomedical research market, today announced the hiring of Susan Aroyan as Chief Strategy Officer. Aroyan will be leading Sanguine's Business Development and Go-To-Market Strategy through growth-building solutions for both clients and partners.

Susan Aroyan, Chief Strategy Officer at Sanguine
Aroyan brings 18 years of experience in the lifescience industry to Sanguine and has held various leadership roles with Boehringer Ingelheim, Pfizer, United States Food and Drug Administration (FDA) and Capgemini. At her previous positions, she was recognized for strategically driving market growth and industry position for her clients through innovative solutions which decrease both cost and, ultimately, time to market. 

"Susan's leadership and deep expertise in healthcare and lifesciences is essential to Sanguine as we scale and expand our offerings and services in the biotech industry," said Brian Neman, CEO of Sanguine. "Susan is a proven leader in building revenue within the life sciences market. She is known for successfully delivering new partnerships and achieving client satisfaction through her superior management. We look forward to achieving our goal of providing patients and researchers with the world's most seamless and efficient clinical trial process with Susan on our team."

"The digital age has brought about new capabilities to improving the speed and cost of clinical trials. Sanguine is changing the clinical research landscape by incorporating the latest technology trends into clinical trials in a compliant and cost-effective manner. I am pleased to join the Sanguine team and drive strategic innovation which benefits the industry from both a pharma and patient perspective," said Aroyan.

Aroyan's hiring comes at a time when Sanguine is expanding their products and growth into clinical development. For more information please visit https://www.sanguinebio.com/

About Sanguine
Sanguine provides services and technology to the personalized medicine and biomedical research market by efficiently conducting at-home clinical trial procedures for major pharmaceutical companies and institutions developing new therapeutic solutions. The company has developed a technology platform that enables clinical research staff to locally conduct clinical study procedures such as biospecimen and medical data collection directly from the patient's homes. This ultimately decreases patient burden while increasing recruitment reach and retention for sponsors. Sanguine hopes to empower patients in the clinical research process by making it easier for them to participate in advancing research for their disease.

The company has fulfilled projects for 20 of the top 40 pharmaceutical and biotechnology companies. The mobile application is currently in used by mobile clinical staff in over 16 cities across the U.S.

Media Contact
Betty Ionescu
[email protected]

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.